WebDoctor Encyclopedia

Chronic myeloid & MDS

Atypical chronic myeloid leukaemia (BCR::ABL1-negative)

Atypical chronic myeloid leukaemia is a rare MDS/MPN overlap blood cancer with high counts of abnormal neutrophils and no Philadelphia chromosome. It mainly affects older adults, often transforms to acute leukaemia, and only stem cell transplant can cure it.

Medically reviewed Last reviewed October 20, 2026

What is atypical chronic myeloid leukaemia?

Atypical chronic myeloid leukaemia (aCML) is a rare blood cancer of the bone marrow. The marrow makes too many neutrophils, a type of white blood cell. Many of them look abnormal (dysplastic), and immature white cells spill out into the blood.

Despite its name, aCML is not a form of chronic myeloid leukaemia (CML). Ordinary CML is driven by the Philadelphia chromosome, which creates the BCR::ABL1 fusion gene, and it responds very well to tablets such as imatinib. aCML lacks this gene change, which is why it is often written as “BCR::ABL1-negative”, and those drugs do not work for it.

aCML belongs to a group called myelodysplastic/myeloproliferative neoplasms (MDS/MPN). These diseases share features of two other groups: the marrow overproduces cells, as in myeloproliferative neoplasms, but the cells are also badly formed, as in myelodysplastic syndromes. The latest WHO classification calls the disease “MDS/MPN with neutrophilia”, while the International Consensus Classification keeps the name aCML (Patnaik and Tefferi, 2023).

It mainly affects older adults, and it is a serious condition. It often causes an enlarged spleen, anaemia and tiredness, and it can change into acute myeloid leukaemia (AML). The only treatment that can cure it is an allogeneic stem cell transplant. Other treatments aim to control blood counts and symptoms (Szuber, Orazi and Tefferi, 2024).

1. Key facts at a glance

Feature Details
Type of cancer Myelodysplastic/myeloproliferative neoplasm with abnormal neutrophils
Other names MDS/MPN with neutrophilia (WHO 2022); aCML, BCR::ABL1-negative
How common Very rare; probably under-recognised in the past
Typical age Usually 60s-70s
Philadelphia chromosome Absent
Common gene changes SETBP1, ASXL1, ETNK1, EZH2, TET2, NRAS/KRAS, SRSF2
Risk of acute leukaemia About 30-40%
Main treatments Stem cell transplant (curative); hydroxycarbamide, hypomethylating agents, ruxolitinib, interferon
Outlook Serious; median survival about 1-2 years

aCML is defined by a pattern of blood and marrow findings rather than by one gene. It must be separated from other conditions that also raise the white cell count.

Condition How it differs from aCML
Chronic myeloid leukaemia (CML) BCR::ABL1 present; responds to tyrosine kinase inhibitors
Chronic neutrophilic leukaemia (CNL) Mature neutrophils without dysplasia; usually a CSF3R mutation; few immature cells in the blood
Chronic myelomonocytic leukaemia (CMML) Raised monocyte count
MDS/MPN, not otherwise specified Does not meet criteria for a specific overlap disease
Myeloid neoplasms with tyrosine kinase fusions For example PDGFRA, PDGFRB or FGFR1 rearrangements; often with eosinophilia
Reactive neutrophilia Caused by infection, inflammation or steroids; not a cancer

Diagnostic features

Feature Typical finding in aCML
White blood cell count 13 x 10^9/L or more
Immature myeloid cells in the blood At least 10% of white cells
Dysplasia Prominent abnormal-looking neutrophils (dysgranulopoiesis)
Monocytes Not increased
Basophils and eosinophils Not notably raised
Blasts Fewer than 20% in blood and marrow
BCR::ABL1 and other fusions Absent

These criteria are summarised from the 2024 review by Szuber, Orazi and Tefferi.

Why it is called “atypical”

When doctors first described the condition, it looked similar to CML in the blood, with a high white count and immature cells. However, it lacked the Philadelphia chromosome and had more dysplasia, so it was labelled “atypical”. We now know that the two diseases are biologically quite different (Fontana, Gambacorti-Passerini and Piazza, 2021).

3. Causes and risk factors

The cause is unknown. The disease arises from acquired mutations in a blood stem cell. These mutations are not inherited.

Factor Notes
Older age The main risk factor
Previous chemotherapy or radiotherapy May increase the risk of myeloid neoplasms generally

Gene changes

Gene Notes
SETBP1 One of the most typical mutations; supports the diagnosis
ASXL1 Very common
ETNK1 Less common but fairly specific
EZH2, TET2, SRSF2 Common in MDS/MPN overlap diseases
NRAS / KRAS Activate growth signals; may be targetable
CSF3R, JAK2, CBL Less frequent

Many of these changes affect signalling pathways such as JAK-STAT and MAPK, which can be targeted by existing drugs (Crisa et al., 2020). Chromosome abnormalities are found in a substantial minority of patients.

4. How does it look

In the blood

Finding Description
White cell count High, often well above 13 x 10^9/L
Neutrophils Increased and dysplastic, for example with poorly segmented nuclei or few granules
Immature cells Promyelocytes, myelocytes and metamyelocytes circulating in the blood
Haemoglobin Often low (anaemia)
Platelets Often low

In the bone marrow

Finding Description
Cellularity Very full (hypercellular)
Granulocytes Greatly increased, with dysplasia
Blasts Fewer than 20%
Other lines Red cell and platelet precursors may also be dysplastic
Fibrosis Present in some patients

On examination

An enlarged spleen is common and may be felt below the left ribs. The liver may also be enlarged.

5. Symptoms

Common symptoms

  • Tiredness and weakness from anaemia
  • Fullness or discomfort under the left ribs from an enlarged spleen
  • Feeling full quickly after small meals
  • Weight loss
  • Night sweats and low-grade fever

Less common symptoms

Symptom Cause
Easy bruising or bleeding Low platelets
Frequent infections Poorly functioning neutrophils
Breathlessness Anaemia
Bone pain Overactive marrow
Sudden left-sided pain Rarely, a splenic infarct

Some people have no symptoms, and the disease is found on a routine blood test.

When to seek medical advice

See your doctor if you have persistent tiredness, unexplained weight loss, night sweats, frequent infections or discomfort under the left ribs. A simple full blood count is the first step.

6. Diagnosis

Test Purpose
Full blood count and blood film Shows high white count, dysplasia and immature cells
Bone marrow aspirate and biopsy Confirms the diagnosis and blast count
Cytogenetics Looks for chromosome changes
BCR::ABL1 testing Excludes CML
Next-generation sequencing panel Detects SETBP1, ASXL1, ETNK1 and other mutations
Tests for PDGFRA, PDGFRB, FGFR1 and JAK2 fusions Excludes other defined diseases
Ultrasound of the abdomen Measures spleen and liver size
Other blood tests Kidney and liver function, uric acid, LDH

Molecular testing has made the diagnosis more precise than it was when it relied on microscope findings alone (Crisa et al., 2020).

Risk assessment

The Mayo Clinic aCML model gives one point each for age over 67, haemoglobin below 10 g/dL and a TET2 mutation (Patnaik and Tefferi, 2023).

Risk group Points Approximate median survival
Low risk 0-1 About 18 months
High risk 2-3 About 7 months

Other high-risk mutations, such as CBL, CEBPA, EZH2, NRAS and U2AF1, have also been identified (Szuber, Orazi and Tefferi, 2024).

7. Treatment

There is no standard treatment proven to change the natural course of aCML, other than transplant. Treatment is guided by risk, symptoms and fitness.

Stem cell transplant

An allogeneic stem cell transplant, using stem cells from a matched donor, is the only potentially curative treatment. It is considered for fitter patients, particularly those with higher-risk disease. It carries significant risks, including graft-versus-host disease and infection.

Medicines to control the disease

Treatment Purpose
Hydroxycarbamide (hydroxyurea) Lowers the white cell count and spleen size
Hypomethylating agents (azacitidine, decitabine) Used especially when dysplasia, anaemia or rising blasts are prominent
Ruxolitinib JAK inhibitor; may reduce spleen size and symptoms, particularly with CSF3R or JAK-STAT changes
Interferon alfa Sometimes used, especially in younger patients
MEK inhibitors (for example trametinib) Under study for RAS-mutated disease
Clinical trials Recommended where available

None of these medicines has been shown to change the long-term course of the disease (Szuber, Orazi and Tefferi, 2024).

Stem cell transplant step by step

Step What happens
Assessment Tests of heart, lung, kidney and general fitness; discussion of risks and benefits
Finding a donor A matched brother or sister, an unrelated volunteer, or a half-matched family member
Preparing the marrow Chemotherapy, sometimes with radiotherapy, to clear the diseased marrow
Transplant Donor stem cells are given through a drip, much like a blood transfusion
Engraftment Over 2-4 weeks, the new cells start making blood; infection protection is essential
Recovery Months of close follow-up for infections and graft-versus-host disease

Before transplant, some patients receive a hypomethylating agent or other treatment to lower the disease burden. The transplant team decides on the type and intensity of preparation based on age and fitness.

Supportive care

Problem Treatment
Anaemia Blood transfusions; sometimes erythropoiesis-stimulating agents
Low platelets Platelet transfusions when needed
Infections Prompt antibiotics; vaccinations
Painful spleen Medicines above; rarely splenic radiotherapy or removal
Iron overload from transfusions Iron chelation

Side effects

Treatment Possible side effects
Hydroxycarbamide Low blood counts, mouth ulcers, skin changes
Azacitidine or decitabine Low counts, infections, nausea, injection-site reactions
Ruxolitinib Anaemia, low platelets, infections
Stem cell transplant Infection, graft-versus-host disease, organ damage

What treatment involves day to day

Stage What to expect
Tablets Daily or several times a week, with regular blood counts
Hypomethylating agents Injections or infusions for 5-7 days every 4 weeks
Transfusions Day-unit visits as needed
Transplant Several weeks in hospital and months of close follow-up

8. Outlook (prognosis)

aCML is a serious disease. Reported median overall survival is about 12-20 months, and transformation to acute myeloid leukaemia occurs in roughly a third of patients (Szuber, Orazi and Tefferi, 2024).

Factor Effect on outlook
Age over 67 Poorer survival
Haemoglobin below 10 g/dL Poorer survival
TET2 mutation Poorer survival
Rising blasts Suggests progression towards AML
Successful stem cell transplant The best chance of long-term survival

Some people live considerably longer than these averages, especially with low-risk features or a successful transplant.

9. Follow-up

Follow-up Purpose
Blood counts every 1-4 weeks Adjust treatment and spot changes
Clinical review Spleen size, symptoms and infections
Repeat bone marrow tests If counts or blasts change
Mutation testing May be repeated to guide treatment
Transplant follow-up Close monitoring for complications

10. Living with atypical chronic myeloid leukaemia

  • Report fever promptly, as infections can become serious quickly
  • Keep vaccinations up to date, after checking which are safe
  • Pace yourself and plan rest to manage tiredness
  • Eat small, frequent meals if your spleen makes you feel full
  • Avoid contact sports if your spleen is enlarged
  • Discuss your priorities and wishes with your care team
  • Seek support from blood cancer charities and MDS/MPN patient groups

11. Frequently asked questions

Question Answer
Is aCML the same as CML? No; it lacks the Philadelphia chromosome and needs different treatment
Will imatinib work? No; imatinib and similar drugs target BCR::ABL1, which aCML does not have
Is it inherited? No; the mutations are acquired
Can it be cured? Only with an allogeneic stem cell transplant
Can it turn into acute leukaemia? Yes, in roughly a third of people
Why has the name changed? WHO now calls it MDS/MPN with neutrophilia to reflect its overlap features
Am I too old for a transplant? Age alone is not the only factor; fitness and other illnesses matter
Why is my spleen enlarged? The spleen fills with excess blood cells and becomes a site of blood production
Will I need transfusions? Many people do at some stage, especially if anaemia worsens

12. Questions to ask your care team

  • What is my risk group, and which mutations does my disease have?
  • Am I a candidate for a stem cell transplant?
  • Which treatment do you recommend to control my counts and spleen?
  • Are there clinical trials I could join?
  • How will we know if the disease is progressing?
  • What should I do if I develop a fever?
  • Who should I contact out of hours?

Resources

  1. Crisa, E. et al. (2020) ‘Atypical chronic myeloid leukemia: where are we now?’, International Journal of Molecular Sciences, 21(18), 6862.
  2. Fontana, D., Gambacorti-Passerini, C. and Piazza, R. (2021) ‘Molecular pathogenesis of BCR-ABL-negative atypical chronic myeloid leukemia’, Frontiers in Oncology, 11, 756348.
  3. Patnaik, M.M. and Tefferi, A. (2023) ‘Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management’, American Journal of Hematology, 98(4), pp. 681-689.
  4. Szuber, N., Orazi, A. and Tefferi, A. (2024) ‘Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management’, American Journal of Hematology, 99(7), pp. 1360-1387.
  5. National Cancer Institute (2026) Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.